Creso Pharma Limited will develop, register and commercialise food grade and medicinal grade cannabis, initially supplying food supplements for animals, entering the human food supplement market in the short term, and later supplying medicinal cannabis based products for chronically ill patients. Governments are progressively legalising the use of medicinal cannabis with 17 countries having decriminalised medicinal cannabis. An investment in Creso Pharma Ltd is considered speculative at this stage, based on the company’s low revenue base and the competitive environment. Independent Investment Research expects the company’s strong management, global strategies and low capital cost business model will provide the company with significant competitive advantages. At this early stage we have not attributed a price target.